Barclays PLC Prelude Therapeutics Inc Transaction History
Barclays PLC
- $327 Billion
- Q2 2024
A detailed history of Barclays PLC transactions in Prelude Therapeutics Inc stock. As of the latest transaction made, Barclays PLC holds 14,601 shares of PRLD stock, worth $30,224. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,601
Previous 20,387
28.38%
Holding current value
$30,224
Previous $97,000
42.27%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding PRLD
# of Institutions
62Shares Held
33.9MCall Options Held
400Put Options Held
100-
Orbimed Advisors LLC San Diego, CA10.9MShares$22.6 Million1.0% of portfolio
-
Baker Bros. Advisors LP New York, NY10.1MShares$21 Million0.51% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY4.13MShares$8.56 Million0.33% of portfolio
-
Boxer Capital, LLC San Diego, CA2.57MShares$5.32 Million0.54% of portfolio
-
Black Rock Inc. New York, NY1.07MShares$2.21 Million0.0% of portfolio
About Prelude Therapeutics Inc
- Ticker PRLD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,369,200
- Market Cap $75.3M
- Description
- Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...